Researchers working on a foam designed to limit internal bleeding of soldiers injured on the battlefield have received $15.5m (£9.6m) from the US military to continue their work.
The foam is formed by two liquids, injected into the body, which mix, expand and harden to create an internal dressing.
Arsenal Medical's product is funded by the Pentagon's Darpa research unit.
One UK surgeon said it could help those far away from a medical facility.
The technology is still in early pre-clinical stages, but has already been tested on pigs.
The firm hopes that the polyurethane polymer foam will help control internal bleeding for at least an hour, increasing the survival chances of troops wounded on the battlefield.
Polyurethane foams are already widely used inside the metal and plastic walls of refrigerators or for thermal insulation.
Once a wounded soldier is transferred to receive proper medical attention, the foam can be easily removed in minutes in a solid block.
According to the pre-clinical data presented at the 2012 annual meeting of the American Association for the Surgery of Trauma in Kauai, Hawaii, the foam raised survival rates for liver injuries after three hours from 8% to 72%, and reduced blood loss sixfold.
"If testing bears out, the foam technology could affect up to 50% of potentially survivable battlefield wounds," said Brian Holloway of Darpa.
Abdominal injuries were especially dangerous, said Dr Michael Walsh, a surgeon at the Royal London Hospital, because traditional methods of stopping blood loss such as compression pads or tourniquets could not be applied.
"Currently for internal bleeding in the abdomen and chest there is nothing that is done pre-hospital to stop the bleeding," he said.
"The best policy currently is for the pre-hospital team to recognise the potential for internal bleeding and to transfer the patient to one of our now designated major trauma centres for rapid assessment and early surgery to stop the bleeding."
He said that the foam technology could be useful to control haemorrhages when a patient was far from a medical facility, or in the case of multiple injuries with competing priorities for treatment.
For example, a severe head injury could be treated once major internal bleeding in the abdomen had been stabilised.
But he added that more research was needed to "demonstrate the safety and efficacy of this product over and above current standards of care for internal bleeding".
Staff would also have to be trained to administer it properly.
The device still needs to be approved by the US Food and Drug Administration.